Current Edition

clinical

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Fortuna Fix, a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells …

Continue Reading →